Clinical relevance of regulatory T cells monitoring in the peripheral blood of ovarian cancer patients
- 1 March 2015
- journal article
- Published by Elsevier in Human Immunology
- Vol. 76 (2-3) , 187-191
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate CancerClinical Cancer Research, 2008
- Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged ≥70 years with advanced ovarian cancer—a study by the AGO OVAR GermanyAnnals of Oncology, 2007
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's LymphomaClinical Cancer Research, 2006
- Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cellsJournal of Clinical Investigation, 2005
- Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic PotentialAmerican Journal of Reproductive Immunology, 2005
- Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluationAnnals of Oncology, 2005
- CD4+CD25+ regulatory T cells in patients with gastrointestinal malignanciesCancer, 2003
- Route of Immunization and the Therapeutic Impact of Recombinant Anticancer VaccinesJNCI: Journal of the National Cancer Institute, 1997
- Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.Journal of Experimental Medicine, 1989